scholarly journals Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow

2011 ◽  
Vol 135 (3) ◽  
pp. 380-385 ◽  
Author(s):  
Sara A. McClintock-Treep ◽  
Robert C. Briggs ◽  
Keith E. Shults ◽  
Leanne A. Flye-Blakemore ◽  
Claudio A. Mosse ◽  
...  
1985 ◽  
Vol 74 (1) ◽  
pp. 207-217
Author(s):  
M. Strath ◽  
C.J. Sanderson

Bone marrow cultures have been established from mice infected with Mesocestoides corti and undergoing parasitic eosinophilia. In the absence of added conditioned medium, eosinophil differentiation ceases, and eosinophils are undetectable by 7 days, whereas neutrophil production continues over several weeks as with normal bone marrow. Eosinophil production can be induced by adding pokeweed mitogen-stimulated spleen supernatants (MSSS) or specific antigen-stimulated spleen supernatants (ASSS) produced from-spleen cells of M. corti-infected mice. In contrast to the continuous production of neutrophils, eosinophil production is transient, suggesting that there is no continued production of eosinophil progenitor cells in these cultures. More eosinophils are produced when MSSS is added at the initiation of cultures, compared to after a delay of 2 weeks, and establishing the cultures at 33 degrees C does not appear to enhance eosinophil production. The eosinophils produced are shown to express the eosinophil differentiation antigen defined by monoclonal antibody NIMP-R13, they produce eosinophil peroxidase in similar amounts to eosinophils taken from mice. They show normal phagocytic activity of antibody-coated erythrocytes and lyse red cells coated with antibodies of IgG1, IgG2a, IgG2b, but not IgM isotypes.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3817-3817
Author(s):  
Andrica de Vries ◽  
Christian M. Zwaan ◽  
Astrid Danen- van Oorschot ◽  
Valerie de Haas ◽  
Henrik Hasle ◽  
...  

Abstract Abstract 3817 Background: Childhood myelodysplastic syndrome (MDS) is a rare disease accounting for less than 5% of all hematological malignancies. In about 50% of the MDS cases an abnormal karyotype is found by conventional karyotyping, of which chromosome 6 is involved in 10%. The immediate-early-response 3 (IER3) gene, which is located on chromosome 6p21, encodes for a glycoprotein that plays a role in the regulation of apoptosis and cell cycle progression. Recently, it was shown that IER3 gene aberrations frequently occur in adult MDS patients, which are not restricted to patients with chromosome 6 aberrations and that low IER3 expression was associated with a worse outcome. Therefore, we investigated the frequency and prognostic impact of IER3 expression in childhood MDS. Methods: IER3 mRNA expression was determined by quantitative real-time PCR in 58 childhood MDS patients of which 17 carried a chromosome 6 aberration, and in normal bone marrow (n=8). In addition, methylation-specific-PCR (MSP) was performed to investigate the methylation status of the promoter region of the IER3 gene, as a plausible cause for the downregulation of IER3. Results: Median IER3 mRNA expression was 0.9% in MDS (range 0.01–73.3% relative to GAPDH expression) and 3.3% in normal bone marrow (range 0.81–85.5% relative to GAPDH expression) (p=0.05). A more than 4-fold decrease in IER3 expression below the mean of healthy controls was found in 74% (43/58) of the childhood MDS patients. There was no difference in IER3 mRNA expression between MDS patients with or without chromosome 6 aberrations (MWU p= 0.89). Also, no difference in IER3 mRNA expression was found between the different WHO-subtypes or between primary versus secondary MDS. Three patients with a chromosome 6p21 rearrangements in the IER3 region based on genomic profiling (array-CGH) showed expression-levels in the range of normal bone marrow. Low IER3 mRNA expression was associated with adverse outcome in childhood MDS patients (Cox regression analysis estimated hazard ratio 0.73, p=0.027, 95% CI-interval 0.55–0.97). The low IER3 expression appeared not to be due to hypermethylation of its promoter region. Conclusion: IER3 expression is low in childhood MDS patients with and without chromosome 6 aberrations and this low expression is associated with poor outcome. However this seems to be due to therapy related mortality, rather than by the increased risk of relapse. The IER3 downregulation is not regulated by hypermethylation of the IER3 promoter region. Disclosures: Hasle: Pfizer: Research Funding.


2009 ◽  
Vol 33 (1) ◽  
pp. 170-173 ◽  
Author(s):  
Fermin M. Sanchez-Guijo ◽  
Jesus M. Hernandez ◽  
Eva Lumbreras ◽  
Patricia Morais ◽  
Carlos Santamaría ◽  
...  

2017 ◽  
Author(s):  
Nancy Berliner ◽  
John M Gansner

This review focuses on anemia resulting from production defects generally associated with marrow aplasia or replacement. The definition, epidemiology, etiology, pathogenesis, diagnosis, differential diagnosis, management, complications, and prognosis of the following production defects are discussed: Acquired aplastic anemia and acquired pure red cell aplasia. Figures depict a leukoerythroblastic blood smear, a biopsy comparing normal bone marrow and bone marrow showing almost complete aplasia, and a marrow smear. A table lists the causes of aplastic anemia. This review contains 3 figures; 1 table; 108 references.


Nature ◽  
1977 ◽  
Vol 265 (5596) ◽  
pp. 736-737 ◽  
Author(s):  
STANLEY ZUCKER ◽  
RITA LYSIK

Sign in / Sign up

Export Citation Format

Share Document